ANVISA encourages citizens and professionals to report adverse drug events via VigiMed and NOTIVISA to monitor the benefit-risk ratio of medications. Covers the global cost of adverse events ($42B annually per WHO), irrational use of medicines (over 50% used inappropriately), rational use principles, ANVISA's role in safety evaluation through risk management plans and international participation, and the importance of public and professional involvement in pharmacovigilance.
Select Mandate HA
Select Mandate Function